Evidence mounts on safety of RAS blockade in COVID-19

A meta-analysis provides ‘solid evidence’ that common antihypertensives do not worsen outcomes, researchers say

Most people with hypertension will be safe to stay on their renin-angiotensin system (RAS) blockers if they develop COVID-19, according to a meta-analysis.